JP2024524552A - 多発性骨髄腫の治療に使用するためのメルフルフェン - Google Patents

多発性骨髄腫の治療に使用するためのメルフルフェン Download PDF

Info

Publication number
JP2024524552A
JP2024524552A JP2024500258A JP2024500258A JP2024524552A JP 2024524552 A JP2024524552 A JP 2024524552A JP 2024500258 A JP2024500258 A JP 2024500258A JP 2024500258 A JP2024500258 A JP 2024500258A JP 2024524552 A JP2024524552 A JP 2024524552A
Authority
JP
Japan
Prior art keywords
stem cell
melflufen
patient
multiple myeloma
refractory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024500258A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2023281007A5 (enExample
Inventor
リンドバリ、ヤーコブ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncopeptides AB
Original Assignee
Oncopeptides AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2109894.2A external-priority patent/GB202109894D0/en
Priority claimed from GBGB2112976.2A external-priority patent/GB202112976D0/en
Application filed by Oncopeptides AB filed Critical Oncopeptides AB
Publication of JP2024524552A publication Critical patent/JP2024524552A/ja
Publication of JPWO2023281007A5 publication Critical patent/JPWO2023281007A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2024500258A 2021-07-08 2022-07-07 多発性骨髄腫の治療に使用するためのメルフルフェン Pending JP2024524552A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB2109894.2 2021-07-08
GBGB2109894.2A GB202109894D0 (en) 2021-07-08 2021-07-08 Novel treatments
GB2112976.2 2021-09-10
GBGB2112976.2A GB202112976D0 (en) 2021-09-10 2021-09-10 Novel treatments
PCT/EP2022/068974 WO2023281007A1 (en) 2021-07-08 2022-07-07 Melflufen for use in the treatment of multiple myeloma

Publications (2)

Publication Number Publication Date
JP2024524552A true JP2024524552A (ja) 2024-07-05
JPWO2023281007A5 JPWO2023281007A5 (enExample) 2025-07-10

Family

ID=82702963

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024500258A Pending JP2024524552A (ja) 2021-07-08 2022-07-07 多発性骨髄腫の治療に使用するためのメルフルフェン

Country Status (5)

Country Link
US (1) US20240307480A1 (enExample)
EP (1) EP4366721A1 (enExample)
JP (1) JP2024524552A (enExample)
TW (1) TW202317084A (enExample)
WO (1) WO2023281007A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024121349A1 (en) * 2022-12-08 2024-06-13 Oncopeptides Ab Therapeutic treatment for haematological cancer based on the level of t-cell function

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002202D0 (sv) 2000-06-13 2000-06-13 Karolinska Innovations Ab New peptides
HUE037863T2 (hu) 2011-04-28 2018-09-28 Oncopeptides Ab Citotoxikus dipeptidek liofilizált készítménye
BR112015009280B1 (pt) 2012-10-26 2022-05-31 Oncopeptides Ab Preparação farmacêutica liofilizada de melfalana flufenamida, composição e kit de combinação de partes
GB201521217D0 (en) * 2015-12-01 2016-01-13 Oncopeptides Ab Dosage regimens
MA53904A (fr) 2018-10-18 2021-08-25 Oncopeptides Ab Composés contenant du deutérium
GB201905477D0 (en) 2019-04-17 2019-05-29 Oncopeptides Ab Novel formulations

Also Published As

Publication number Publication date
US20240307480A1 (en) 2024-09-19
TW202317084A (zh) 2023-05-01
WO2023281007A1 (en) 2023-01-12
EP4366721A1 (en) 2024-05-15

Similar Documents

Publication Publication Date Title
RU2318517C2 (ru) Комбинация, включающая n-{5-[4-(4-метилпиперазинометил)бензоиламидо]-2-метилфенил}-4-(3-пиридил)-2-пиримидинамин и химиотерапевтический агент
US20250144023A1 (en) Melflufen dosage regimens for cancer
HUE029027T2 (en) Procedures for Multiple Myeloma Treatment Using HuLuc63 and Bortezomib Combination Therapies
AU2021200370B2 (en) Boron-containing proteasome inhibitors for use after primary cancer therapy
JP2025160168A (ja) Ｓｅｒｄ投薬レジメンの組み合わせを使用してがんを治療する方法
JP2024524552A (ja) 多発性骨髄腫の治療に使用するためのメルフルフェン
EP3914257B1 (en) Combination of a bcl-2/bcl-xl inhibitor with osimertinib
CN117940119A (zh) 美氟芬用于多发性骨髓瘤的治疗
US20240207281A1 (en) Methods of treating b-cell lymphoma using combination therapy
CN120936360A (zh) 包括心脏耐受性hdac抑制剂的方法和组合物
HK1260696B (en) Melflufen dosage regimens for cancer
HK1260696A1 (en) Melflufen dosage regimens for cancer
JP2022527532A (ja) メルフルフェンによるａｌアミロイドーシスの治療
HK1245107A1 (zh) 多发性骨髓瘤的罗尼哌他组合治疗

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20240823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250702

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250702